B. Mark Evers, MD Director, Markey Cancer Center University of Kentucky

Transcription

1 April 13 Time Topic Speaker 8-8:30 Welcomes Robert DiPaola, MD, PhD Dean, College of Medicine B. Mark Evers, MD Director, Markey Cancer Center 8:30-9:00 Overview of Immunology and Basis of Immunotherapy Val Adams, PharmD Associate Professor, College of Pharmacy 1. Describe the key components of the immune system 2. Understand the mechanism of action of new immunotherapies General Session I: Clinical Updates in Immunotherapy, Solid Tumors 9:00-9:45 Keynote 1: Recent Advances in the Treatment of Melanoma and Renal Cell Cancers Jeffrey Sosman, MD Feinberg School of Medicine Northwestern University 9:45-10:15 The Role of Immunotherapy in the Treatment of Lung Cancer 1. Apply results of immunotherapy clinical trials to the treatment melanoma and renal cell cancer 2. Describe the place in therapy of novel immunotherapies. John L. Villano, MD, PhD, 1. Compare and contrast the use and effectiveness of immunotherapy in the treatment of lung cancer 2. Outline the effective use of cancer genetic data when considering immunotherapy to inform treatment selection and potential immune response 10:15-10:30 Discussion Session I Speakers 10:30-11:00 Break 11:00-11:45 Workshop 1 (Participants pick one) Moderated by: Jessica Croley, MD Medical Oncologist KentuckyOne Health 1) Immunotherapy in Challenging Populations Tom Badgett, MD, PhD Assistant Professor of Pediatrics Lowell Anthony, MD Greg Monohan, MD

2 Associate a) Describe the role of immunotherapy in pediatric and geriatric populations b) Discuss the use of immunotherapies in the immune compromised patient 2) Managing the Adverse Effects of Immunotherapy Aju Mathew, MD, FACP, MPhil Assistant Rachael Morgan, PharmD, BCOP Clinical Pharmacist Specialist Holly Chitwood, APRN Clinical Instructor of Pediatrics a) Develop strategies to manage common adverse effects of immunotherapies b) Recognize adverse effects of immunotherapies 3) Optimization and Interpretation of Immunotherapy Biomarkers Virgilius Cornea, MD Assistant Professor of Pathology and Laboratory Medicine Kurt Hodges, MD, MBA Associate Professor of Pathology and Laboratory Medicine a) Discuss the appropriate use of clinically relevant immunotherapy biomarkers b) Understand the results presented in a immunotherapy biomarker report 4) Unique Aspects of Immunotherapy: Radiologic Assessment of Response and Rheumatological Management Michael Brooks, MD Associate Professor of Radiology and Internal Medicine Aleksander Lenert, MD, FRCPC Assistant

3 a) Develop strategies to assess clinical responses to immunotherapy b) Recognize and manage immunotherapy induced rheumatic adverse effects 11:45-1:15 Lunch with Poster Session Meeting attendees are invited to submit abstracts of their ongoing work for presentation during the poster session. Due date for abstracts is March 15, Abstracts can be submitted at the conference website 1:15-2:00 Workshop 2 (Participants pick one) 1) Immunotherapy in Challenging Populations Tom Badgett, MD, PhD Assistant Professor of Pediatrics Lowell Anthony, MD Greg Monohan, MD Associate a) Describe the role of immunotherapy in pediatric and geriatric populations b) Discuss the use of immunotherapies in the immune compromised patient 2) Immunotherapy Clinical Trials at MCC Jacob Hodskins, MD, MS Medical Oncologist Owensboro Health Medical Group a) Describe unique considerations for clinical trial designs in immunotherapeutic agents b) Assess the current immunotherapy clinical trial portfolio for relevance to your patient population c) Identify gaps in the current clinical trial portfolio 3) Combining Immunotherapy and Radiation Ron McGarry, MD, PhD Professor a) Describe the influence of immunotherapy on the abscopal effect

4 2:00-2:15 Break General Session II: Biomarkers and Response Assessment 2:15-2:30 Biomarkers of Response I: Established 2:30-2:45 Biomarkers of Response II: Emerging 2:45-3:15 Immune therapy in Hematological Malignancies: An Overview 3:15-4:00 Keynote 2: CAR-T cell therapy 4:00-4:15 Discussion Session II Speakers b) Address strategies to optimize timing and sequencing of combination therapy for maximal synergy 4) The Immune System in Cancer Development Tian Gao, PhD Professor, Molecular & Cellular Biochemistry Christine Brainson, PhD Assistant Professor, Toxicology and Cancer Biology a) Understand the role of the innate immune response in colon cancer carcinogenesis b) Describe the role of the immune system in lung cancer development and sensitivity to therapies Jill Kolesar, PharmD, MS Professor, College of Pharmacy 1) Assess the role of PD-L1 testing in predicting response to immunotherapy 2) Understand and apply tumor mutation burden and microsatellite instability as predictive biomarkers Don Cohen, PhD Professor, College of Medicine 1) List methods for quantifying and characterizing T cells 2) Understand novel methods for assessing immune response to immunotherapy G. Hildebrandt, MD Professor, College of Medicine 1) Describe immunological principles in treating patients with hematologic cancers 2) Understand the clinical development of immune checkpoint inhibitors in the treatment of lymphoma Renier Brentjens, MD, PhD Director, Cell Therapeutics Memorial Sloan Kettering Cancer Center 1) Describe the process for generating CAR-T cells 2) Understand the place in therapy of CAR-T cells for hematologic malignancies 4:15-4:30 Wrap-up and Introducing ORIEN network and Total Cancer Care Moderated by: Adam Lye, MD Medical Oncologist Hardin Memorial Health Jill Kolesar, PharmD 1) Assess the strategies of the ORIEN network 2) Develop strategies to enroll patients in Total Cancer Care

5 April 14 PM Hands on Workshop 8-8:45 NGS Tests, What They Are and When to Order Them Jill Kolesar, PharmD Professor, College of Pharmacy 1) Describe the basic methods and samples used for next generation sequencing 2) Differentiate common next generation sequencing tests 8:45-9:15 Introduction to MCC Guidance Documents Elizabeth Beckman, PharmD Clinical Knowledge Management Analyst UK HealthCare 1) Discuss the process for guidance document development 2) Develop strategies for using guidance documents in clinical practice 9:15-9:45 Update on Lung Cancer, When to Test and Emerging Therapies Zhonglin Hao, MD, PhD Associate 9:45-10:15 Update on Ovarian Cancer, When to Test and Emerging Therapies 10:15-10:30 Break 10:30-11:00 Update on GI Cancer, When to Test and Emerging Therapies 11:00-11:30 Update on Breast Cancer, When to Test and Emerging Therapies 1) Determine appropriate lung cancer select targeted therapies for lung cancer patients Rachel Miller, MD Associate Professor of Obstetrics and Gynecology 1) Determine appropriate ovarian cancer select targeted therapies for ovarian cancer patients Ravneet Thind, MD Assistant Professor of Internal Medicine 1) Determine appropriate GI cancer select targeted therapies for GI cancer patients Ed Romond, MD Professor, College of Medicine 1) Determine appropriate breast cancer

6 11:30-12 Wrap-up select targeted therapies for breast cancer patients